Professor Maggie Dallman, Principal of the Faculty of Natural Sciences and Professor of Immunology at Imperial College London
Maggie heads the Faculty of Natural Sciences encompassing the departments of Chemistry, Physics, Mathematics and Life Sciences at Imperial College London. She also sits on the Biotechnology and Biological Sciences Research Council Strategy Advisory Board, the Scientific Advisory Board of the Institute for Animal Health, the Board of the National Centre for Replacement, Refinement and Reduction of Animals in Research and is a Non-executive Director of the Imperial College Healthcare NHS Trust. Her research interests are to understand how uncontrolled immune and inflammatory responses contribute to a wide range of debilitating conditions such as obesity, diabetes and rheumatoid arthritis.
Dr Roy Evison, Retired GP
Dr Roy Evison is a retired GP, who during his working life looked after two boys with X-linked CGD. He also had part time management appointments with an Acute Hospital Trust and then the local PCT. After retirement he joined the CGD Research Trust, but after 2 year as a trustee had to step down due to outside pressures. However, he has retained a consultative role on the Medical Panel and the Gene Therapy group, which are of great interest to him, and helps out the Charity as and when he can.
Professor Majlinda Lako, Professor of Stem Cell Science, Newcastle University, Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne
Linda is a leading expert in stem cell biology. She leads a research team involved with the study of factors that control the differentiation of stem cells into different cell types and the development of stem cell lines to study and help treat genetic diseases. She is an associate editor of the journal ‘Stem Cells’ and acts as scientific member of international grant review panels including the Connecticut Stem Cell Peer review committee and Agence Nationale de la Recherche in France.
Andrew Orchard, CGD Society Trustee
Andrew is an IT consultant and data analyst and the lay panel member on this advisory board. He is a founder member of the charity and father to a son affected with the X-linked form of CGD and has a nephew who successfully received a bone marrow transplant in 2002 with a sibling donor and is now deemed to be CGD free. Andrew is keen to ensure the charity continues in its search for a cure for CGD and research into developing better treatments to tackle the new health issues which are appearing as the CGD population gets older and for the mother carriers of the disorder.
Professor Tom Rogers, Head of Clinical Microbiology, Trinity College Dublin, St James's Hospital, Dublin
After training in medicine in Dublin Tom was Lecturer in Bacteriology at Westminster Medical School. There he worked with colleagues who were pioneering paediatric bone marrow transplantation for genetic disorders including CGD. This encouraged his interest in improving diagnosis and therapy of fungal infections and particularly invasive aspergillosis, a life-threatening condition that affects people with CGD. This work continued at Hammersmith Hospital, Imperial College, until in 2004 he became head of Clinical Microbiology at Trinity College Dublin. He is President of the Healthcare Infection Society and immediate past President of the Association of Medical Microbiologists.
Professor Dirk Roos, Department of Blood Cell Research, Sanquin Research Centre, Amsterdam
Dirk is a biochemist and professor of immunology and a world-leading expert on CGD. His special research focus is on the enzyme affected in CGD and his laboratory carries out mutational analysis studies on samples from people with CGD from all over the world in order to precisely pinpoint which part of the CGD proteins are affected. His research has been devoted to understanding how these proteins work and what exactly the effects of the mutations are. He sits on the CGD Registry Committee for the European Society for Immunodeficiency Diseases. Text not yet approved by Prof Roos.
Professor Adriano Rossi, Chair of Respiratory and Inflammation Pharmacology at the University of Edinburgh/MRC Centre for Inflammation Research
Adriano is an expert in neutrophil and macrophage biology, the cell types affected in CGD, and in inflammation. He leads a research group involved in understanding the molecular mechanisms that control inflammatory processes and is helping develop new strategies for the treatment of inflammatory lung diseases such as chronic bronchitis, emphysema, idiopathic pulmonary fibrosis and asthma.
Professor Reinhard Seger, Consultant paediatrician, University Children's Hospital, Zurich
Reinhard is a consultant paediatrician and a world-leading expert in the clinical management of CGD and primary immunodeficiencies. He trained as a clinician in Switzerland, France (Hôpital Necker in Paris) and the USA (Duke University Medical Center) and gained a Master of Science degree in Immunology at Birmingham University before setting up a paediatric bone marrow transplantation (BMT) unit at the Children’s Hospital in Zurich. He sits on the European Group for Blood and Marrow Transplantation Working Party for Inborn Errors.
Professor Len Seymour, Chair of Committee, Professor of Gene Therapies, University of Oxford
Len is a world authority on gene based treatments with over 120 publications, and is Professor of Gene Therapies at the University of Oxford. He was the founding President of the British Society for Gene Therapy and is currently Secretary General of the European Society for Gene & Stem Cell Therapy. His research activities are particularly directed towards new treatments for cancer at the interface of stem cell and genetic technologies including the delivery of therapeutic viruses and gene constructs. Len is the scientific founder and former Board member of Hybrid Biosystems Ltd.
Dr Simon Travis, Clinical Director of Gastroenterology and Endoscopy, John Radcliffe Hospital, Oxford
Simon is a consultant gastroenterologist at the John Radcliffe Hospital, Oxford and current President-Elect of the European Crohn’s and Colitis Organisation (ECCO). He has played a key role in the development of ECCO guidelines for the management of Crohn’s Disease and ulcerative colitis. His major research interests focus on novel therapy, clinical prediction and outcomes in clinical trials of IBD.